Allianz Asset Management GmbH Reduces Position in Becton, Dickinson and Company (BDX)

Allianz Asset Management GmbH trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 89.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 326,534 shares of the medical instruments supplier’s stock after selling 2,876,740 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.14% of Becton, Dickinson and worth $63,985,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. boosted its stake in Becton, Dickinson and by 5.9% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 6,905 shares of the medical instruments supplier’s stock worth $1,267,000 after buying an additional 387 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Becton, Dickinson and during the first quarter worth $3,787,000. Two Sigma Securities LLC acquired a new position in Becton, Dickinson and during the first quarter worth $493,000. Level Four Advisory Services LLC boosted its stake in Becton, Dickinson and by 23.1% during the first quarter. Level Four Advisory Services LLC now owns 3,634 shares of the medical instruments supplier’s stock worth $666,000 after buying an additional 683 shares during the last quarter. Finally, Sii Investments Inc. WI lifted its stake in shares of Becton, Dickinson and by 14.1% in the 1st quarter. Sii Investments Inc. WI now owns 1,700 shares of the medical instruments supplier’s stock valued at $311,000 after purchasing an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 88.46% of the company’s stock.

In related news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company (NYSE BDX) traded up $0.15 on Wednesday, reaching $219.07. The company had a trading volume of 963,700 shares, compared to its average volume of 1,319,580. Becton, Dickinson and Company has a 1 year low of $161.29 and a 1 year high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The firm has a market cap of $49,909.01, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the prior year, the company earned $2.12 EPS. Becton, Dickinson and’s revenue was down 2.0% on a year-over-year basis. research analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a dividend of $0.75 per share. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.37%. Becton, Dickinson and’s dividend payout ratio is presently 62.80%.

Several equities analysts have recently commented on BDX shares. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Tuesday, October 31st. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Cowen reaffirmed a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research note on Monday, August 14th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $217.08.

COPYRIGHT VIOLATION NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://stocknewstimes.com/2017/12/06/allianz-asset-management-gmbh-reduces-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply